

中国科技论文统计源期刊（中国科技核心期刊）


ISSN 1006-1703

CN 11-3294/R

标记免疫分析与临床

BIAOJI MIANYI FENXI YU LINCHUANG
LABELED IMMUNOASSAYS AND CLINICAL MEDICINE

2014年第21卷 第5期 Vol. 21 No.5 2014




肿瘤多学科诊治和
肿瘤标志物进展专刊

ISSN 1006-1703



万方数据



中国同辐股份有限公司
China Isotope & Radiation Corporation

标记免疫分析与临床

Labeled Immunoassays and Clinical Medicine

双月刊

1994 年 2 月创刊

第 21 卷

第 5 期(总 97 期)

2014 年 10 月 25 日出版

主管

中国核工业集团公司

主办

中国同辐股份有限公司

编辑

标记免疫分析与临床编辑委员会

主编 田亚平

社长 朱清峰

出版

《标记免疫分析与临床》杂志社

印刷

中国人民解放军第 4210 工厂

发行

公开发行

北京市报刊发行局

订购

全国各地邮政局

邮发代号:2-307

邮购

《标记免疫分析与临床》杂志社

定价

每期 20 元

全年 120 元

地址

北京市西城区三里河二区甲 1 号 305 室

邮编 100045

电话

(010)68515701

(010)68517801

网址

www.chinabjmy.com

E-mail

bjmy@china-isotope.com

中国标准连续出版物号

ISSN 1006-1703

CN 11-3294/R

目 次

专 论

- 肿瘤相关标志物研究进展 陈永康, 齐军 (493)

临床研究

- 外周血多参数基因诊断模型对于原发性肝细胞癌诊断价值的评价 张朋军, 田亚平 (499)

- SPECT/CT 骨显像对脊柱单发阳性病灶的应用价值 张乐乐, 吴文芳, 刘任从, 等 (503)

- CA19-9、增强 MRI 和 PET/CT 在胰腺癌诊断及分期中的价值 王治国, 石庆学, 郭佳, 等 (507)

- 经 CDFI 引导¹²⁵I 粒子植入治疗转移性浅表肿瘤疗效观察 付巍, 唐毅, 秦凌云, 等 (511)

- 新型肿瘤标志物: Mu-GlcNAc 范振符, 陈智周, 范飞舟, 等 (514)

- 胸腺肽 β4 对乳腺癌化疗相关心脏毒性的诊断价值 薛剑, 袁芳, 于农, 等 (516)

- 血清学指标联合筛查对胃癌诊断的临床意义 周扬, 田亚平 (520)

- 分化型甲状腺癌术后胸腺浓聚¹³¹I 的临床分析 王叙馥, 张勤, 刘新峰, 等 (525)

- 癌胚抗原监测吉非替尼治疗晚期非小细胞肺癌的临床疗效初步研究 张国强, 周炎, 吴黎明 (528)

- 乳腺癌患者血清 IL-6、IL-1β、TNF-α 的变化及其临床意义 凌存保, 吴隽松 (532)

- 乳腺浸润性导管癌患者联合检测 CA27-29 和 CA15-3 的临床分析 鲁传翠, 张珏, 陈建中 (535)

- 血清 CA125 检测在肝癌腹水中的诊断价值 王永斌, 郑雪娟, 邓智勇, 等 (537)

- 核素⁸⁹SrCl₂ 治疗骨转移瘤患者的临床观察 胡德胜, 石磊 (540)

- ¹⁸F-FDG PET/CT 盆部延迟显像在原发性膀胱癌诊断和局部分期中的临床价值 汪太松, 赵晋华, 宋建华, 等 (543)

- ¹³¹I 治疗老年与非老年分化型甲状腺癌淋巴结转移的临床观察 崔学军, 张蓉蓉 (546)

- 肺癌骨转移患者^{99m}Tc-MDP 显像和鳞癌标志物对评估疗效的临床研究 段永强,罗鹏程,陈曦,等(549)
 家属的护理干预对脑胶质瘤患者围手术期应激状态的影响 冯曼玲(553)

基础研究

- 靶向 CD20 和 HLA-DR 分子 Crossmab 的设计与构建表达 曾静,王津京,刘然,等(557)
 细胞色素 P450 2C19 基因多态性与肺癌遗传易感性 金欣,左向华,薛剑,等(564)
 脑胶质瘤患者 LMO-1 和 LMO-4 基因表达水平的改变及其意义 董成亚,李昊文,刘丽,等(568)
 microRNA-155 在小儿急性髓性白血病中的差异表达及分析 徐丽华,杨乃超,颜青,等(571)

方法研究

- 胃蛋白酶原、胃泌素-17 及 Hp-IgG 抗体对胃癌、萎缩性胃炎患者胃粘膜状况的血清学评价 刘中娟,郭子建,赵召霞,等(576)
¹⁸F-FDG PET 诊断淋巴瘤骨髓浸润的价值 META 分析 汪太松,赵晋华,乔文礼(581)
¹³¹I-BDI-1 在荷人膀胱癌裸鼠体内的生物分布研究及辐射剂量评估 郝攀,张春丽,闫平,等(585)
 螺旋 CT 血管成像和灌注成像技术对胃癌血供和血流动力学评价 王勇,成瑶,张晓勇(589)
 上海地区多个肿瘤标志物正常参考值的初步确定 李鼎,陆云,刘兴党(593)
 表面健康人群血清附睾蛋白 4 参考范围调查 李丹,刘春雷,田露,等(596)

综述

- 肝癌患者循环肿瘤细胞的检测及其临床应用研究进展 马清,陈水平,陈建魁(599)
 循环肿瘤细胞与肿瘤恶性行为间的关系 史珂玮,刘春芳(603)
 前列腺癌基因 3 的研究进展 谭思嘉,贾瑞鹏(608)
 前列腺特异性膜抗原为靶标治疗激素难治性前列腺癌的研究进展 邵国强,崔璨,王自正(613)

技术经验交流

- 专科护士参与“肿瘤多学科联合会诊”的管理探讨 闫虹,姜燕平,刘建琴,等(618)
 肿瘤标志物的临床检验教学探讨 温庆祥,石瑾,李蔷(621)

病例报告

- 鼻腔异位化生性脑膜瘤 1 例 田云霄,郑神英(623)

- 英文摘要目次 (III)

Labeled Immunoassays and Clinical Medicine

Bimonthly Established in February 1994 Volume 21, Number 5 (Cumulated No. 97)

Oct 25, 2014

Responsible Institution China National Nuclear Corporation Sponsor China Isotope & Radiation Corporation Editing Editorial Board of Labeled Immunoassays and Clinical Medicine Editor-in-Chief TIAN Ya-ping(田亚平) President ZHU Qing-feng(朱清峰) Publishing Labeled Immunoassays and Clinical Medicine Press Printing The PLA 4210 Factory Distribution Beijing Publishing Bureau Mail-Order Labeled Immunoassays and Clinical Medicine Press Address Room 305, 1A 2nd Block, Sanlihe, West District, Beijing 100045, China Tel (010) 68515701 (010)68517801 CNNS ISSN 1006 - 1703 CN 11 - 3294/R	<h2>CONTENTS IN BRIEF</h2> <h3>Special Article</h3> <p>Research Progress of Tumor Related Markers CHEN Yong-kang, QI Jun (493)</p> <h3>Clinical Investigation</h3> <p>Multi-parameter Genes Expression Profiling in Peripheral Blood for the Detection of Hepatocellular Carcinoma ZHANG Peng-jun, TIAN Ya-ping (499)</p> <p>SPECT/CT Bone Scan for Differential Diagnosis of Spinal Single Positive Lesions WANG Le-le, WU Wen-fang, LIU Ren-cong, et al. (503)</p> <p>Clinical Value of CA19-9, Contrast-enhanced MRI and PET-CT in the Diagnosis and Staging of Pancreatic Cancer WANG Zhi-guo, SHI Qing-xue, GUO Jia, et al. (507)</p> <p>Clinical Significance ofCDFI-guided ¹²⁵I Seed Implantation in The Treatment of Metastatic Superficial Tumor FU Wei, TANG yi, QIN Ling-yun, et al. (511)</p> <p>A New Tumor Marker: Mu-GlcNAc FAN Zhen-fu, CHEN Zhi-zhou, FAN Fei-zhou, et al. (514)</p> <p>The Diagnostic Value of Thymosin β4 on Chemotherapy-related Cardiotoxicity of Breast Cancer XUE Jian, YUAN Fang, YU Nong, et al. (516)</p> <p>Clinical Significance of the Combined Detection of Serologic Parameters in the Diagnosis of Gastric Cancer ZHOU Yang, TIAN Ya-ping (520)</p> <p>Thymus Accumulation of Iodine-131 in Post-operative Patients with Differentiated Thyroid Cancer WANG Xu-fu, ZHANG Qin, LIU Xin-feng, et al. (525)</p> <p>Research of CEA Detection on Monitoring of Clinical Effects of Gefitinib in Treatment of Advanced Non Small Cell Lung Cancer ZHANG Guo-qiang, ZHOU Yan, WU Li-ming (528)</p> <p>Clinical Significance of Serum IL-6, IL-1β and TNF-α in Patients with Breast Cancer LING Cun-bao, WU Juan-song (532)</p> <p>Clinical Significance of Combined Detection of CA27-29 and CA153 in Patients with Breast Infiltrating Ductal Carcinoma LU Chuan-cui, ZHANG Yu, CHEN Jian-zhong (535)</p> <p>Diagnostic Value of CA125 in Patients with Ascites Hepatoma WANG Yong-bin, ZHENG Xue-juan, DENG Zhi-yong, et al. (537)</p> <p>Clinical Observation of ⁸⁹SrCl₂ Therapy in Patients with Bone Metastases HU De-Sheng, SHI Lei (540)</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The Clinical Value of ¹⁸F-FDG PET/CT Delayed Imaging of Pelvis for Detection and Locoregional Staging of Urinary Bladder Cancer	(543)
WANG Tai-song, ZHAO Jin-hua, SONG Jian-hua, et al.	(543)
Clinical Observation of ¹³¹I Therapy for Lymph Node Metastases from Differentiated Thyroid Cancer in the Elderly Versus Non-elderly Patients	(546)
CUI Xue-jun, ZHANG Rong-rong	(546)
Evaluation of Curative Effect in Lung Cancer Patients with Bone Metastases by Plasma Squamous Cell Carcinomas Markers	(549)
DUAN Yong-qiang, LUO Peng-cheng, et al.	(549)
Effects of Nursing Intervention on Family Members on Stress State of Patients with Glioma During the Perioperative Period	(553)
FENG Man-ling	(553)

Basic Research

Design, Construction and Expression of the Crossmab Bispecific Antibody Molecular for Targeting CD20 and HLA-DR	(557)
ZENG Jing, WANG Jin-jing, LIU Ran, et al.	(557)
Association Between Genetic Polymorphisms of Cytochrome P450 2C19 and the Risk of Lung Cancer	(564)
JIN Xin, ZUO Xiang-hua, XUE Jian, et al.	(564)
Expression and Significance of LMO-1 and LMO-4 in Human Glioma	(568)
DONG Cheng-ya, LI Hao-wen, LIU Li, et al.	(568)
The Differential Expression and Clinical Analysis of MicroRNA-155 in Pediatric Acute Myeloid Leukemia	(571)
XU Li-hua, YANG Nai-chao, YAN Qing, et al.	(571)

Assay Development

Serological Assessment of Gastric Mucosa Using Pepsinogens, Gastrin-17 and Hp-IgG in Patients with Gastric Cancer and Atrophic Gastritis	(576)
LIU Zhong-juan, GUO Zi-jian, ZHAO Zhao-xia, et al.	(576)
Value of ¹⁸F-FDG PET for Detection of Bone Marrow Infiltration in Patients Affected by Lymphoma: A Meta-Analysis	(581)
WANG Tai-song, ZHAO Jin-hua, QIAO Wen-li	(581)
Biodistribution and Dosimetry of ¹³¹I-BDI-1 in Nude Mice Bearing Human Bladder Carcinoma	(585)
HAO Pan, ZHANG Chun-li, YAN Ping, et al.	(585)
Evaluation of CTA and CTPI in the Blood Supply and Hemodynamic of Gastric Cancer	(589)
WANG Yong, CHENG Yao, ZHANG Xiao-Yong	(589)
Establishment of the Reference Range of Multi-Tumor Markers for Healthy People in Shanghai	(593)
LI Ding, LU Yun, LIU Xing-dang	(593)
Serum HE4 Concentration in Apparently Healthy Individuals	(596)
LI Dan, LIU Chun-lei, TIAN Lu, et al.	(596)

Review

Progress of Circulating Tumor Cell Analysis and Clinical Application in Patients with Liver Cancer	(599)
MA Qing, CHEN Shui-ping, CHEN Jian-kui	(599)
The Relationship Between Circulating Tumor Cells and Tumor Malignant Behaviors	(603)
SHI Ke-wei, LIU Chun-Fang	(603)
Research Progress of Prostate Cancer Gene 3	(608)
TAN Si-jia, JIA Rui-peng	(608)
Advances in Prostate Specific Membrane Antigen Targeted Therapy of Hormone Refractory Prostate Cancer	(613)
SHAO Guo-qiang, CUI Can, WANG Zi-zheng	(613)

Exchange of Technologies and Experience

The Research for Specialized Nurses to Participate in Tumor Multidisciplinary Consultation	(618)
YAN Hong, JIANG Yanping, LIU Jianqin, et al.	(618)

社长	朱清峰
副社长	王丁泉
编辑	陈泮藻 张增武 李凌 黄梦桃 李英丽
本期责任编辑	李英丽
本期英文审校	杜进

本刊由北京中同蓝博临床检验所、北京北方生物技术研究所协办

期刊基本参数：CN 11 - 3294/R * 1994 * B * A4 * 132 * zh * P * ¥20.00 * 2000 * 35 * 2014-10



金斯尔
Gcell

九强生物




我们的实力：



863计划

自2011年起，九强生物成为“863计划”
《体外诊断技术产品开发重大项目》
“心脑血管慢性损伤及急救指标等体
外诊断试剂的研制”项目成员之一。

2014年，九强生物牵头863计划《人体营养素检测关键
技术与产品开发》主题项目“人体维生素与抗氧化能力
等检测系统及配套试剂的研发”课题。
课题编号：2014AA022304。



彩虹计划
Customer Requirement Planning
客户关怀计划

网络信息平台
微信服务平台
专属宣传彩页

我们汇聚力量，为您私人定制。



CysC国家标准物质制备

九强生物实验室参与CysC国家标准物质研制工作：

- 承担标准物质制备工作
- 参与标准物质定值工作
- 完成标准物质互换性测试



连续九年上榜福布斯

2006年-2014年，九强生物连续九年
被评为“福布斯中国潜力企业”。

追求卓越 成就未来

北京九强生物技术股份有限公司

金斯尔·九强生物旗下体外诊断试剂品牌

免费咨询电话：800 810 0197/1373